An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma

Trial Profile

An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Amatuximab (Primary) ; Cisplatin; Pemetrexed
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Sponsors Morphotek
  • Most Recent Events

    • 23 May 2014 According to ClinicalTrials.gov reocrd, status changed from active, no longer recruiting to completed.
    • 23 May 2014 According to ClinicalTrials.gov reocrd, status changed from active, no longer recruiting to completed.
    • 05 Nov 2013 Planned end date changed from 1 Feb 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top